Holobiome has announced a research collaboration with Johnson & Johnson Innovation, focusing on the creation of novel microbiome therapeutics.
The partnership follows a similar agreement with the company that was announced in January of 2018, focused around developing microbiome therapeutics for sleep disorders and related comorbidities.
"Recent findings continue to highlight the link between the human microbiome – the trillions of bacteria that live on and in us – and diseases of the central and enteric nervous systems. At Holobiome, we are excited to work with the Johnson & Johnson Consumer team to help bridge these emerging scientific advancements into potential solutions for patients", said Philip Strandwitz, CEO and co-founder of Holobiome.
"This second collaboration brings our goals one step closer to reality."